N4 Pharma (N4P) Competitors GBX 0.40 +0.03 (+6.67%) As of 07/25/2025 11:18 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock N4P vs. HELD, HLN, BXP, HIK, HCM, INDV, AMYT, AGY, APH, and ANCRShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), and Animalcare Group (ANCR). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Its Competitors Hellenic Dynamics Haleon Beximco Pharmaceuticals Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Animalcare Group N4 Pharma (LON:N4P) and Hellenic Dynamics (LON:HELD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation. Is N4P or HELD more profitable? Hellenic Dynamics has a net margin of 0.00% compared to N4 Pharma's net margin of -18,399.86%. N4 Pharma's return on equity of -90.68% beat Hellenic Dynamics' return on equity.Company Net Margins Return on Equity Return on Assets N4 Pharma-18,399.86% -90.68% -56.00% Hellenic Dynamics N/A -364.21%N/A Does the media favor N4P or HELD? In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Hellenic Dynamics'average media sentiment score. Company Overall Sentiment N4 Pharma Neutral Hellenic Dynamics Neutral Which has stronger earnings and valuation, N4P or HELD? N4 Pharma has higher revenue and earnings than Hellenic Dynamics. N4 Pharma is trading at a lower price-to-earnings ratio than Hellenic Dynamics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioN4 Pharma£8.84K194.84-£1.63M-£0.35-1.16Hellenic DynamicsN/AN/A-£5.22M-£3.550.00 Do institutionals & insiders hold more shares of N4P or HELD? 0.1% of Hellenic Dynamics shares are held by institutional investors. 18.0% of N4 Pharma shares are held by company insiders. Comparatively, 72.9% of Hellenic Dynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryHellenic Dynamics beats N4 Pharma on 5 of the 9 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding N4P and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£1.72M£2.18B£5.74B£3.02BDividend Yield3.12%2.92%4.71%5.02%P/E Ratio-1.164.2328.41160.65Price / Sales194.84587.23443.64278,114.26Price / Cash2.2510.3536.1827.97Price / Book0.8911.038.654.70Net Income-£1.63M£21.15B£3.25B£5.90B7 Day Performance0.50%1.91%4.31%0.41%1 Month Performance1.27%6.12%11.60%7.20%1 Year Performance-23.81%3.01%35.38%70.37% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.40+6.7%N/A-22.0%£1.72M£8.84K-1.165Gap UpHELDHellenic DynamicsN/AGBX 0.01flatN/AN/A£14KN/A0.00N/AHLNHaleon1.076 of 5 starsGBX 365.81+0.2%GBX 457+24.9%+3.7%£33.02B£11.07B30.7725,408News CoverageBXPBeximco PharmaceuticalsN/AGBX 39.10-1.0%N/A-2.0%£26.65B£7.08T4.205,500HIKHikma Pharmaceuticals3.7302 of 5 starsGBX 2,004-1.2%GBX 2,560+27.7%+6.3%£5.56B£3.74B19.669,100HCMHUTCHMEDN/AGBX 258-3.0%N/A-11.6%£2.80B£771.01M-65.851,760Gap DownINDVIndivior2.8828 of 5 starsGBX 1,238+1.6%GBX 1,650+33.3%+25.4%£1.93B£1.40B-1,026.481,000Gap UpHigh Trading VolumeAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 8-1.2%N/A+66.7%£393.21M£72.18M-7.71612Gap UpHigh Trading VolumeAPHAlliance Pharma2.0059 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 261.13-0.7%N/A-4.7%£179.03M£84.90M4.87220 Related Companies and Tools Related Companies Hellenic Dynamics Alternatives Haleon Alternatives Beximco Pharmaceuticals Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Animalcare Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:N4P) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.